E-LIB Suche - Ergebnisse für: Feldman, T.

1

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE..:

Nastoupil, L. J. ; Kamdar, M. ; Chavez, J. C....
Hematological Oncology. 41 (2023) S2 - p. 212-214 , 2023

Link: https://doi.org/10.1002/..

2

Variation Of Coronary Atherosclerosis Across Spectrum Of In..:

Nasir, K. ; Lahan, S. ; Maqsood, M....
Journal of Cardiovascular Computed Tomography. 17 (2023) 4 - p. S41-S42 , 2023

Link: https://doi.org/10.1016/..

3

Sexual problems in MS: Sex differences and their impact on ..:

Kaplan, T.B. ; Feldman, T. ; Healey, B....
Multiple Sclerosis and Related Disorders. 74 (2023) - p. 104672 , 2023

Link: https://doi.org/10.1016/..

4

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:

Torka, P. ; Feldman, T. ; Savage, K....
Hematological Oncology. 41 (2023) S2 - p. 161-162 , 2023

Link: https://doi.org/10.1002/..

5

P‐BT‐23 | The Impact of Cryopreservation Media on the Funct..:

Tatari‐Calderone, Z. ; Awatefe, H. ; Feldman, T..
Transfusion. 63 (2023) S5 - p. , 2023

Link: https://doi.org/10.1111/..

6

Encouraging complete responses (CRs) with CDK9 inhibitor AZ..:

Zinzani, P. L. ; Feldman, T. ; Collins, G....
Hematological Oncology. 41 (2023) S2 - p. 568-569 , 2023

Link: https://doi.org/10.1002/..

7

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023

Link: https://doi.org/10.1002/..

8

Phase 1 trial of KT‐333, a STAT3 degrader, in patients with..:

Smith, S. ; Olszewski, A. ; Starodub, A. N....
Hematological Oncology. 41 (2023) S2 - p. 567-568 , 2023

Link: https://doi.org/10.1002/..

9

OA1‐AM23‐MN‐12 | Evaluation of Novel Biochemical Tags as Al..:

Feldman, T. ; Tatari‐Calderone, Z. ; Brown, B.
Transfusion. 63 (2023) S5 - p. , 2023

Link: https://doi.org/10.1111/..

10

Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of..:

Danish, A. ; Della Pia, A. ; Varughese, T....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e463-e464 , 2023

Link: https://doi.org/10.1016/..

11

Evaluation of ctDNA in a phase I/II trial in relapsed or re..:

Soong, D. ; Thieblemont, C. ; Karavitis, J....
Hematological Oncology. 41 (2023) S2 - p. 326-328 , 2023

Link: https://doi.org/10.1002/..

12

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology. 41 (2023) S2 - p. 351-353 , 2023

Link: https://doi.org/10.1002/..

13

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REM..:

Thieblemont, C. ; Karimi, Y. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 142-144 , 2023

Link: https://doi.org/10.1002/..

14

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere. 6 (2022) - p. 102-103 , 2022

Link: https://doi.org/10.1097/..

15

P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DAC..:

Lee, H. ; Flinn, I. W. ; Melear, J....
HemaSphere. 6 (2022) - p. 979-980 , 2022

Link: https://doi.org/10.1097/..